European Companies Search Engine
EU funding (€3,933,202): BIO-MICRO: Biomarkers and Intervention Outcomes in Micronutrient Optimization Hor9 Jul 2025 EU Research and Innovation programme "Horizon"
Overview
Text
BIO-MICRO: Biomarkers and Intervention Outcomes in Micronutrient Optimization
European micronutrient (MN) guidelines explicitly recommend to replete any MN deficiency in critically ill patients. MNs are crucial for immune defence, cellular metabolism and as antioxidant. Critically ill patients have increased requirements for MNs which can result in severe deficiencies and worse clinical outcomes. There are currently no accurate methods to diagnose MN deficiencies in critically ill patients. MN plasma concentrations are substantially affected by inflammation. MN concentrations in erythrocytes and leukocytes or new functional markers may better reflect real deficiencies. Furthermore, most intervention trials with high-dose MN monotherapy yielded mixed results on clinical outcomes. Due to the absence of accurate monitoring tools of MN body status, all patients received fixed high-dose MN monotherapy. Personalized MN therapy based on subphenotyping of patients and accurate estimation of individual metabolic demands in all phases of disease may yield better outcome than this one-size-fits-all strategy. In addition, more insight in the complex interplay between MNs and the role of MNs in post-ICU phase is necessary to guide future trials. BIO-MICRO consists of physicians, biologists, methodologists, trialists, health scientists, clinical chemists, patient representatives and industrial participants and aims to train innovative research fellows with interdisciplinary and intersectoral skills to develop the urgently needed strategies for MN personalized therapy in critically ill patients. They will develop new analytics for reliably determination MN body status, investigate subphenotypes of patients likely to benefit from MN therapy, enable guidance with appropriate timing of MN therapy, investigate the interplay between MNs and explore the role of MNs in the rehabilitation phase. This will ultimately lead to significantly decreased mortality and organ dysfunctions, shorter ICU stay, improvement of quality of life and significant cost reductions.
Funded Companies:
| Company name | Funding amount |
| DeWolfPact B.V. | ? |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | €580,545 |
| DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG POTSDAM REHBRUECKE | €290,272 |
| Randox Teoranta | €682,174 |
| REINER HAGA MEDISCH DIAGNOSTISCH CENTRUM B.V. | €305,286 |
| STICHTING AMSTERDAM UMC | €610,572 |
| Stichting Martini Ziekenhuis | €305,286 |
| STICHTING ZIEKENHUIS GELDERSE VALLEI | €305,286 |
| Universita Degli Studi Di Foggia | €563,510 |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | €290,272 |
Source: https://cordis.europa.eu/project/id/101226686
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: DeWolfPact B.V., The Hague, Netherlands.
The visualizations for "DeWolfPact B.V. - EU funding (€3,933,202): BIO-MICRO: Biomarkers and Intervention Outcomes in Micronutrient Optimization"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
